Hims & Hers Health Inc.（紐交所代碼：HIMS）在週一收盤後公佈了其第四季度業績。以下是該季度的關鍵數據。 Hims & Hers Health報告季度GAAP每股收益爲0.11美元，符合分析師預期。季度收入爲4.8114億美元，超過了分析師預期的4.7031億美元，並高於去年同期的2.4662億美元。 Hims & Hers的訂閱用戶數量增長至220萬，較2023年同比增長45%。第四季度毛利率爲77%，較2023年第四季度的83%有所下降。 Hims & Hers Health首席執行官Andrew Dudum表示：“2024年是Hims & Hers非常出色的一年，我們繼續構建一個利用個性化和技術的平臺，與傳統醫療系統截然不同。現在超過200萬用戶信任Hims & Hers，幫助他們在健康之旅中取得進展，每天都有數以千計的新用戶加入。” 展望未來：Hims & Hers預計2025年第一季度收入爲5.2億至5.4億美元，調整後的息稅折舊攤銷前利潤（EBITDA）爲5500萬至6500萬美元，反映了11%至12%的調整後EBITDA利潤率。 公司預計2025年全年收入爲23億至24億美元，調整後的EBITDA爲2.7億至3.2億美元，反映了12%至13%的調整後EBITDA利潤率。 根據Benzinga Pro的數據，Hims & Hers Health的股價在週一盤後下跌17.66%，至42.25美元。

以上內容來自Benzinga Earnings專欄，原文如下：

Hims & Hers Health Inc. (NYSE:HIMS) reported its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the quarter. 

The Details: Hims & Hers Health reported quarterly GAAP earnings of 11 cents per share, which met the analyst consensus estimate. Quarterly revenue came in at $481.14 million, which beat the analyst consensus estimate of $470.31 million and is an increase over revenue of $246.62 million from the same period last year.

Hims & Hers subscribers grew to 2.2 million, up 45% year-over-year in 2024. Gross margin was 77% for the fourth quarter of 2024 compared to 83% for the fourth quarter of 2023.

Read Next: Palantir Extends Losses, Microsoft Slides: What’s Driving Markets Monday? 

“2024 was a fantastic year at Hims and Hers as we continue to build a platform that leverages personalization and technology unlike any traditional healthcare system,” said Andrew Dudum, Hims & Hers Health CEO.

“Over 2 million subscribers now entrust Hims & Hers to aid them in their journey to better health — with thousands more joining daily,” Dudum added.

Outlook: For the first quarter of 2025, Hims and Hers expects revenue of $520 million to $540 million and adjusted EBITDA of $55 million to $65 million, reflecting an adjusted EBITDA margin of 11% to 12%.

For the full year 2025, the company expects revenue of $2.3 billion to $2.4 billion and adjusted EBITDA of $270 million to $320 million, reflecting an adjusted EBITDA margin of 12% to 13%.

HIMS Price Action: According to data from Benzinga Pro, Hims & Hers Health shares are down 17.66% after hours at $42.25 Monday.  

Read Next: 

• Financial Crime Weekly: $1.4 Billion Ethereum Stolen In Largest Crypto Hack Ever, SEC Creates Cyber And Emerging Technologies Unit

Image: Shutterstock